Fibroscan to monitor immunotherapy in liver cancer
Part of Cancer, Digestive system clinical trials.
This study uses a special ultrasound (Fibroscan) to check how well immunotherapy is working for advanced liver cancer. It may help doctors see if the treatment is effective without needing a biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer confirmed by scans or biopsy
- Your liver is still working well (Child-Pugh A score if you have cirrhosis)
- You are able to take care of most daily tasks (ECOG performance status 0, 1, or 2)
- You have no high-risk signs of bleeding in your stomach or esophagus, and no history of variceal bleeding
- You have not had local treatments like embolization or ablation before, and have not had a liver transplant
- You do not have severe autoimmune disorders, uncontrolled blood pressure, or blood vessel problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how liver cancer changes during immunotherapy and looks for biological markers that may predict treatment response. It helps doctors understand why some patients benefit more from treatment.
This trial uses a special ultrasound (Fibroscan) to check your liver health and see if you can safely reduce your anti-rejection medications. It is for people who are at least 2 years past a liver transplant and whose liver is working well.
This study looks at different first-line immunotherapy treatments for people with advanced liver cancer that cannot be treated with surgery or local therapies. It aims to understand how well these treatments work and how they affect the body's immune system.
This study looks at how doctors can use imaging scans to predict how well immunotherapy will work for people with liver cancer that cannot be removed by surgery. Participants must have already received immunotherapy and have had baseline scans.
This study looks at how well a combination of liver-directed therapy and immunotherapy works for people with liver cancer that cannot be removed by surgery. It aims to find markers in your blood that might predict if the treatment will shrink the tumor enough to allow surgery later.
This trial tests how well immunotherapy drugs work for people with advanced liver cancer that cannot be treated with surgery. It focuses on patients whose liver is still working fairly well.
Hear when a new Hepato Cellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.